NEW YORK, July 27, 2017 /PRNewswire/ --
If you want a Stock Review on OPK, ARRY, IMMU, or TGTX then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. Pre-market this morning, DailyStockTracker.com reviews the following four stock within the Biotech space: Opko Health Inc. (NASDAQ: OPK), Array BioPharma Inc.
On Wednesday, shares in Miami, Florida headquartered Opko Health Inc. gained 0.16%, ending the day at $6.41. The stock recorded a trading volume of 2.32 million shares. The Company's shares are trading below their 50-day moving average by 1.09%. Moreover, shares of Opko Health, which engages in the diagnostics and pharmaceuticals business in the US, Ireland, Chile, Spain, Israel, and Mexico, have a Relative Strength Index (RSI) of 50.07.
On July 18th, 2017, Xenetic Biosciences, Inc., a clinical-stage biopharmaceutical company buoyed by Opko Health, announced that its 2017 Annual Meeting of Stockholders, which was scheduled for that day, was convened and adjourned, without any business being conducted due to lack of the requisite quorum. The Annual Meeting has been adjourned to 12:00 p.m. local time on August 16th, 2017, at the offices of Marcum LLP, 53 State Street, 17th Floor, Boston, Massachusetts 02109. OPK complete research report is just a click away at:
Shares in Boulder, Colorado headquartered Array BioPharma Inc. ended the day 1.15% lower at $7.77 with a total trading volume of 1.48 million shares. The stock is trading below its 50-day moving average by 5.45%. Shares of the Company, which focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and Asia/Pacific, have an RSI of 38.56.
On July 18th, 2017, Array BioPharma and Amgen announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through the former's proprietary platform that leverages its expertise in chemistry and early lead development. The complimentary report on ARRY can be downloaded at:
At the close of trading on Wednesday, shares in Morris Plains, New Jersey headquartered Immunomedics Inc. finished 1.73% higher at $8.80 with a total trading volume of 956,112 shares. The stock has advanced 1.03% in the last one month, 59.42% over the previous three months, and 139.78% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 7.53% and 64.26%, respectively. Additionally, shares of Immunomedics, which focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases, have an RSI of 53.45.
On July 10th, 2017, Immunomedics reported that its phase-II clinical trial results with sacituzumab govitecan (IMMU-132) have been published in two, prominent cancer journals: Clinical Cancer Research and Journal of Clinical Oncology. The study involved a total of 104 lung cancer patients, including advanced small-cell and non-small-cell lung cancer patients who relapsed after, or were refractory to, prior treatment with standard chemotherapy or immune checkpoint inhibitors. Sign up for your complimentary research report on IMMU at:
New York headquartered TG Therapeutics Inc.'s shares recorded a trading volume of 896,181 shares at the end of yesterday's session. The stock closed the day 3.96% higher at $11.80. The Company's shares have advanced 1.72% in the past month and 153.76% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.66% and 42.01%, respectively. Additionally, shares of TG Therapeutics, which focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the US, have an RSI of 55.82. Get free access to your research report on TGTX at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Nocturnal polyuria refers to increased urine output during night, without an associated increase in ...
Nootropics are drugs or substances which improve cognition that are being increasingly used ...
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...View All